The impact of the gut-liver axis on intrahepatic NK cell activity: Identifying modulators of efficacy in donor-derived NK cell therapy for HCC recurrence after liver transplantation
Authors
Affiliations
Abstract
Introduction: Liver tissue-resident natural killer (lrNK) cells are critical for eliminating circulating tumor cells (CTCs) via TRAIL-mediated pathways. We previously conducted Phase 1 clinical trials of donor-derived activated lrNK cell infusion in 24 living donor liver transplantations (LT) in Japan and 17 deceased donor LT in the USA. While safety was confirmed and a dose-dependent correlation with post-transplant outcomes was observed, individual variations in lrNK cell activity and clinical fluctuations remained significant challenges. To elucidate the factors influencing lrNK cell function, we focused on the gut-liver axis, hypothesized to be a key regulator of hepatic anti-tumor immunity.
Method: Clinical outcomes from the Phase 1 trials were reviewed to establish the baseline efficacy of lrNK cell therapy. To investigate the impact of the intestinal environment on lrNK cell activity, we utilized mouse models of bowel obstruction and low-fiber diet-induced constipation. We analyzed intrahepatic anti-tumor immunity, lrNK cell activity, and TRAIL expression levels. Cytokine profiles, including IL-1beta, IL-6, and IL-33, were assessed in the liver and colon to identify mediators of lrNK cell suppression. We also evaluated clinical data from patients with obstructive colorectal cancer to correlate intestinal conditions with hepatic tumor recurrence.
Results: The clinical trials demonstrated that higher doses of infused lrNK cells were associated with improved recurrence-free survival. However, experimental data revealed that intestinal dysfunction significantly impaired this defense. In the bowel obstruction model, intrahepatic lrNK cell activity and TRAIL expression were significantly reduced, mediated by elevated inflammatory cytokines (IL-6 and IL-33). This suppression was reversed upon relief of the obstruction. Similarly, the constipation model (low-fiber diet) showed a marked decrease in TRAIL-dependent cytotoxicity, with localized increases in IL-1beta and IL-6 in the colon and liver, while perforin and IFN-gamma levels were unaffected. Clinical analysis supported these findings, showing higher recurrence rates in patients with compromised intestinal motility.
Conclusion: Our findings suggest that the gut-liver axis is a major determinant of intrahepatic lrNK cell activity. The effectiveness of donor-derived NK cell therapy for preventing HCC recurrence after LT may be optimized by managing the intestinal environment and targeting specific inflammatory cytokines. Based on these insights, multi-center Phase 2 trials are being prepared to further validate lrNK cell therapy in conjunction with gut-liver axis considerations.